SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001562180-22-005049
Filing Date
2022-06-10
Accepted
2022-06-10 17:30:16
Documents
2
Period of Report
2022-05-31

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 3  
1 PRIMARY DOCUMENT primarydocument.xml 3 1809
2 POA_RUSSELL poa_russell.txt EX-24 4604
  Complete submission text file 0001562180-22-005049.txt   7846
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Issuer) CIK: 0001831363 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O TERNS PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address
Russell Kerry Strong (Reporting) CIK: 0001927137 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39926 | Film No.: 221010008